Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis (Pro-Muco)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00750932
Recruitment Status : Completed
First Posted : September 11, 2008
Last Update Posted : February 27, 2017
Information provided by (Responsible Party):
University Hospital, Tours

Brief Summary:

The purpose of the proposed project is to characterize the neutrophile proteases which participate in the chronic inflammatory phenomenon associated with the cystic fibrosis and which are responsible for the degradation of the lung tissue.

The respiratory failure which results from it is one of main causes of the fatal evolution of this pathology but the anti-inflammatory therapies based on the use of antiproteases targeting specifically the soluble elastase did not end, until now, in the hoped results.

The identification of the other noxious targets is a crucial element to give new orientations to the anti-inflammatory strategies based on the administration of antiproteases which remain a promising way.

Condition or disease
Cystic Fibrosis

Study Type : Observational
Actual Enrollment : 52 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Study of the Biodistribution of PMN Serine Proteases in Sputum of Patients Affected by Cystic Fibrosis: Towards New Anti-inflammatory Therapies
Study Start Date : January 2008
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Minor with cystic fibrosis
Adult with cystic fibrosis

Biospecimen Retention:   Samples With DNA
Whole blood Sputum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adults and children with cystic fibrosis

Inclusion Criteria:

  • Man /woman older than 18 years (for adult and group)
  • Child aged 6 to 18 years (for child group)
  • Suffering from cystic fibrosis in stable condition, ie not having presented thrust acute attack of the broncho-pulmonary or hospitalization for treatment of his illness during the previous 2 weeks

Exclusion Criteria:

  • colonized by Burkholderia cepacia ou Stenotrophomonas maltophilia
  • non smoker (control group)
  • Without history or respiratory respiratory disease known (control group)
  • Antibiotic treatment and / or anti-inflammatory drug (NSAID or corticosteroids) in the 2 weeks prior to the inclusion in the study (control group)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00750932

CHRU de Tours
Tours, France, 37044
Sponsors and Collaborators
University Hospital, Tours
Principal Investigator: Patrice DIOT, PHD Tours Hospital

Responsible Party: University Hospital, Tours Identifier: NCT00750932     History of Changes
Other Study ID Numbers: AOHP07-PD Pro-Muco
N° ID RCB:2007-A00511-52
CPP: 2007-R17
First Posted: September 11, 2008    Key Record Dates
Last Update Posted: February 27, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases